Polyclonal Antibodies Market (2026 - 2033)

Polyclonal Antibodies Market Summary

The global polyclonal antibodies market size was valued at USD 1.9 billion in 2025 and is projected to grow from USD 2.1 billion in 2026 to USD 3.5 billion in 2033, at a CAGR of 8.1% from 2026 to 2033. North America dominated the global market, accounting for the largest revenue share of 40.0% in 2025. This is mainly attributed to the growing prevalence of infectious and chronic diseases, such as cancer, across the globe, increasing technological advancements in antibody-based drugs, and rising R&D activities in the biopharmaceutical industry.

Moreover, as compared to monoclonal antibodies, the manufacturing cost of polyclonal antibodies is lower. Polyclonal antibodies (pAbs) are widely used in qualitative and quantitative biological analysis and various diagnostic testing. The rising acceptance of standard laboratory tests, such as Western blot analysis, microarray assays, cell imaging, and immunohistochemistry (IHC), is projected to propel market growth.

The increasing global burden of cancer is another significant factor driving demand for antibodies in research and diagnostic applications. The most common cancers include lung, breast, rectum & colon, and prostate cancer. According to the American Cancer Society’s Cancer 2025 report, approximately 66,890 new leukemia cases are expected to be diagnosed in the U.S. in 2025, along with nearly 23,540 deaths attributable to the disease. Polyclonal antibody-based therapies are widely used in oncology research and treatment, including for lymphoma, leukemia, and solid tumors, due to their ability to recognize multiple antigenic epitopes and enhance immune-mediated targeting of cancer cells. Growing investments in cancer immunology and cell-based therapies are further expanding antibody-related research activities. For example, in February 2025, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded approximately USD 898,263 to support the development of in vivo CAR macrophages for glioblastoma treatment, highlighting continued investment in advanced immunotherapy research.

Furthermore, rabbits remain one of the preferred host species for polyclonal antibody production due to their ability to generate robust immune responses against a wide range of antigens and to produce high-titer, epitope-specific antibodies with minimal nonspecific background reactivity. These characteristics make rabbit-derived polyclonal antibodies highly valuable for vaccine research, biologics development, and immunogenicity assessment, contributing to the market growth.

Furthermore, governments and public research organizations worldwide are supporting antibody research through funding programs, infrastructure development initiatives, and investments in biotechnology innovation. Such trends are encouraging advancements in antibody discovery, production, and research, thereby supporting the continued growth of the global market.

Analyst Perspective

The polyclonal antibodies market is witnessing steady growth, driven by the rising prevalence of cancer and infectious diseases and increasing demand for sensitive diagnostic testing. Their high assay sensitivity, broad antigen recognition, and cost-effectiveness support widespread use in research and clinical diagnostics. Despite challenges such as batch variability and cross-reactivity, advancements in purification technologies and growing research investments are expected to drive long-term market growth.

Product Insights

The secondary antibodies segment dominated the market in 2025, accounting for more than 55.0% of the market share. Secondary Abs bind to primary Abs that are raised against the target antigen and amplify the signal through various detection methods, including ELISA, Western blotting, and Immunohistochemistry. In addition, secondary Abs are typically produced by immunizing host animals, such as rabbits, goats, or mice, along with the immunoglobulin (Ig) of the same species as the primary antibody. Thus, this leads to the production of polyclonal secondary Abs that can recognize multiple epitopes on primary Abs, henceforth increasing the sensitivity and specificity of the assay.

The primary antibodies segment is expected to grow at the fastest CAGR of around 6.0% during the forecast period. The increasing adoption of primary antibody (pAb)- based assays in clinical diagnostics and the rising demand for high-quality & diverse primary Abs are factors contributing to the growth of the segment. Primary Abs are essential reagents for various clinical assays, including Western Blotting, ELISA, and Immunohistochemistry for the identification of disease biomarkers. Thus, as the demand for personalized medicine and biomarker-based diagnostics continues to grow, the primary antibody segment in the pAbs market is expected to grow further.

Application Insights

The diagnostics segment dominates the market for polyclonal antibodies, with a share of around 60.0% in 2025, and is anticipated to grow with the highest CAGR of more than 5.0% from 2026 to 2033. pAbs are considered ideal reagents in hemagglutination reactions and diagnostic assays due to their ability to recognize epitopes on the targeted molecules. Moreover, pAbs are relatively inexpensive to produce compared with mAbs, as they can be generated by immunizing animals such as rabbits, goats, or mice with the target antigen, which stimulates a polyclonal antibody response. In addition, the polyclonal antibody used in applications such as ELISA, Western Blot, and many others is less likely to produce false negatives because it recognizes multiple epitopes on the target antigen.

Biomedical research is projected to grow significantly from 2026 to 2033. This growth can be attributed to their versatility, ease of production, diverse range of binding specificities, and ability to detect a wide range of biomolecules. Furthermore, rapid advancements in AI-enabled antibody discovery, high-throughput screening, and structure-guided biologics design platforms are supporting the growth. In May 2025, research studies highlighted the increasing adoption of machine learning and multimodal foundation models in antibody discovery and engineering[2] . These technologies are accelerating the identification and optimization of high-affinity antibody candidates for cancer, autoimmune diseases, and other therapeutic applications. Such advancements are contributing to broader improvements in antibody research workflows, supporting growth in biomedical research activities that utilize both monoclonal and polyclonal antibodies.

Source Insights

The rabbit segment dominated the market in 2025, with a market share of around 50.0%, due to rabbits' rapid immune response to small molecules, haptens, and post-translational modifications. Moreover, rabbit Abs have greater affinity and specificity than those from other animals. Rabbit-sourced antibodies (Abs) are highly specific and bind to various proteins in the picomolar range. Abs sourced from rabbits are highly specific and exhibit improved immunologic response, thereby facilitating better recognition of diseases during diagnosis. Companies such as GenScript Biotech continued to strengthen their antibody development and production capabilities through an integrated biologics services portfolio, which includes rabbit-based polyclonal and monoclonal antibody generation platforms. The company's large-scale antibody production services and dedicated rabbit immunization facilities support the growing demand in the rabbit segment.

The mouse is expected to grow at the fastest CAGR of around 8.0% from 2026 to 2033. Mice are more widely available in research laboratories than other animals for the production of Abs via immunization protocols. Moreover, the growth factors for mouse-derived pAbs include their high homology to human proteins. Mice share a high degree of genetic and protein sequence similarity with humans, making them ideal hosts for generating pAbs that cross-react with human proteins.

End User Insights

The hospitals & diagnostic centers segment dominated the market with a market share of around 60.0% in 2025 and is anticipated to grow with the highest CAGR of more than 5.0% during the forecast period. Due to the rising prevalence of chronic & infectious diseases, growing cases of cancer, and increasing demand for pAbs-based assays in diagnostic centers, the demand for hospitals & diagnostic centers is anticipated to increase during the forecast period. Furthermore, growing investments in hospitals & diagnostic centers are expected to boost the segment's growth. For instance, in May 2025, Apollo Hospitals launched AI-powered, fully automated diagnostic laboratories capable of processing high sample volumes with improved accuracy and faster turnaround times, thereby strengthening the role of hospitals and diagnostic networks in precision testing and disease diagnosis.

The pharmaceutical & biotechnology companies segment is projected to show significant growth over the forecast period, owing to increasing demand for pAbs in drug discovery & development and growing investment in biologics. In addition, the demand for polyclonal antibodies is primarily driven by their extensive use in drug discovery, target validation, biomarker identification, assay development, and preclinical research. Pharmaceutical and biotechnology companies continue to increase investments in oncology, immunology, infectious disease, and biologics research, creating a strong need for reliable antibody-based research tools. As companies accelerate therapeutic development programs and expand R&D activities, demand for custom and research-grade polyclonal antibodies is rapidly growing.

Regional Insights

North America dominated the industry, with a market share of 40.0% in 2025. This large market share is attributed to several factors, including numerous biotechnology and pharmaceutical companies, advanced technology and infrastructure, a strong focus on innovation, a stringent regulatory environment, and a well-developed healthcare system. In October 2024, GigaGen, a U.S.-based subsidiary of Grifols, advanced its recombinant polyclonal antibody platform through a BARDA-funded program focused on developing antibody therapies for infectious diseases and biological threats. The initiative highlights continued investment in advanced antibody technologies and strengthens North America's position as a leading region for antibody research, development, and innovation.

Asia Pacific Polyclonal Antibodies Market Trends

The polyclonal antibodies market in the Asia Pacific is anticipated to register the highest CAGR of 10.0% during the forecast period. The pAbs market is driven by several factors, including the increasing prevalence of chronic diseases, rising demand for personalized medicine, growing investments in research and development, and advancements in healthcare infrastructure in countries such as India, China, and South Korea. As a result, the pAbs market in the Asia Pacific region is expected to continue to grow rapidly in the coming years.

Key Polyclonal Antibodies Company Insights

Companies in the market are focusing on manufacturing novel medical products and advancing technology. In addition, mergers, acquisitions, and collaborations for novel product development are among the initiatives implemented by major players.

Key Polyclonal Antibodies Companies

The following key companies have been profiled for this study on the polyclonal antibodies market:

• Thermo Fisher Scientific Inc.

• Merck KGaA

• Abcam plc.

• ProteoGenix

• Proteintech Group, Inc.

• Bio-Rad Laboratories Inc.

• BPS Bioscience, Inc.

• R&D Systems, Inc.

• Agilent Technologies, Inc.

• Atlas Antibodies

• CUSABIO TECHNOLOGY LLC

• ROCKLAND IMMUNOCHEMICALS, INC.

Recent Developments

• In April 2026, Regeneron Pharmaceuticals partnered with TriNetX to access large-scale de-identified EHR data covering approximately 300 million patients, integrating it with genomic and proteomic datasets to strengthen AI-driven drug discovery, biomarker identification, and biologics research. 

• In December 2025, Samsung Biologics expanded its global CDMO footprint by acquiring GSK’s biologics manufacturing facility in Rockville, Maryland, marking its first U.S. production site and strengthening its large-scale biologics and antibody manufacturing capabilities while improving cross-regional supply chain integration between Asia Pacific and North America.

• In June 2025, Bio-Rad Laboratories expanded its anti-idiotypic antibody portfolio and SpyCatcher reagent range to support bioanalysis and antibody drug development workflows. The expansion includes recombinant monoclonal antibodies for key biotherapeutics, strengthening development of pharmacokinetic (PK), anti-drug antibody (ADA), and biosimilar assays across biologics research and therapeutic monitoring applications.

Polyclonal Antibodies Market Report Scope

Global Polyclonal Antibodies Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global polyclonal antibodies market report based on product, application, source, end user, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)

  • Primary Antibodies

  • Secondary Antibodies

• Application Outlook (Revenue, USD Billion, 2021 - 2033)

  • Biomedical Research

  • Diagnostics

• Source Outlook (Revenue, USD Billion, 2021 - 2033)

  • Rabbits

  • Goats

  • Sheep

  • Mouse

  • Others

• End User Outlook (Revenue, USD Billion, 2021 - 2033)

  • Pharmaceutical & Biotechnology Companies

  • Hospitals & Diagnostic Centers

  • Academic & Research Center

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait